Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases

American Journal of Therapeutics

Volumn 17, Issue 1, 2010, Pages 17-22

  Baghaei, Parvaneh ^a   Tabarsi, Payam ^a   Chitsaz, Ehsan ^a   Saleh, Masoumeh ^a   Marjani, Majid ^a   Shemirani, Shahrzad ^a   Pooramiri, Majid Valiollah ^a   Kazempour, Mehdi ^a   Farnia, Parisa ^a   Fahimi, Fanak ^a   Mansouri, Davood ^a   Masjedi, Mohammadreza ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE

Author keywords

Drug induced hepatitis; Risk factors; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HEALTH CENTER; HUMAN; LIVER FUNCTION TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 76149090884     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818f9eae     Document Type: Article

References (30)

1. Shaberg T. The dark side of antituberculosis therapy: adverse events involving liver function. Eur Respir J. 1995; 4:1247-1249.
2. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
3. Schaberg T, Rebhan K, Lode H. Risk factors for sideeffects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026-2030.
4. Ormerod LP. Hepatotoxicity of antituberculosis drugs. Thorax. 1996;51:111-113.
5. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis. 1978;117:991-1001.
6. Franks AL, Binkin NJ, Snider DE, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104:151-155.
7. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculosis treatment including isoniazid. Hepatology. 1995;21:929-932.
8. Ormerod LP. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Committee of the British Thoracic Society. Thorax. 1990;45:403-408.
9. Chitturi S, Farrell G. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2002:1059-1128.
10. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145-155.
11. Ostapowicz GM, Fontana R, Schiodt F, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137: 947-954.
12. Saukkonen JJ, Cohn DL, Jasmer RM, et al. American Thoracic Society, An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952.
13. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 3rd ed. WHO/CDS/TB/2003. 313. Geneva, Switzerland: World Health Organization; 2003.
14. Saukkonen JJ, Cohn DL, Jasmer RM, et al. American Thoracic Society Documents. An Official ATS Statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952.
15. Sharifi-Mood B, Kouhpayeh HR, Salehi M. Incidence of hepatotoxicity due to antitubercular medicine and assessment of risk factors, Zahedan, Iran. J Med Sci. 2006; 6:44-47.
16. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916-919.
17. Bothamley GH. Treatment, tuberculosis, and human leukocyte antigen [editorial]. Am J Respir Crit Care Med. 2002;166:907-908.
18. Pande JN, Singh SPN, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51:132-136.
19. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007;11: 78-84.
20. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-1477.
21. Algerian Working Group/British Medical Research Council cooperative study. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis. 1984;129:921-928.
22. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother. 2004;38:1074-1079.
23. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al. The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8:1499-1505.
24. Wong WM, Wu PC, Yuen MF, et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31:201-206.
25. Ungo JR, Jones D, Ashkin D, et al. Anti-tuberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871-1876.
26. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16:403-406.
27. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. East Mediterr Health J. 2000;6: 1114-1116.
28. Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77:335-340.
29. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996;77:37-42.
30. Teleman MD, Chee CB, Earnest A, et al. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis. 2002;6: 699-705.